SCHEMBL16013129

SCHEMBL16013129

C[SiH](C)C(C)(C)COCc1c(Br)cccc1[N+](=O)[O-]

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 4/20 0.35
ALDH1A1 P00352 7/20 0.34
HTT P42858 1/20 0.34
TSHR P16473 3/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NPSR1 Q6W5P4 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
GPR35 Q9HC97 1/20 0.32
POLB P06746 1/20 0.32
KMT2A Q03164 4/20 0.32
NPC1 O15118 2/20 0.31
RAB9A P51151 2/20 0.31
RECQL P46063 1/20 0.31
HSD17B10 Q99714 1/20 0.31
LMNA P02545 1/20 0.31
MEN1 O00255 3/20 0.30
CYP2D6 P10635 2/20 0.30
KDM4E B2RXH2 2/20 0.30
MAPT P10636 2/20 0.30
CYP1A2 P05177 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28715778 0.82 TDP1 (0.44) TDP1ALDH1A1HTTTSHRSMN1; SMN2
SCHEMBL18185065 0.79 TDP1 (0.42) TDP1ALDH1A1TSHRSMN1; SMN2GPR35
SCHEMBL18185046 0.78 TDP1 (0.41) TDP1ALDH1A1HTTTSHRSMN1; SMN2
SCHEMBL18185025 0.77 ALDH1A1 (0.40) TDP1ALDH1A1TSHRSMN1; SMN2NPSR1
SCHEMBL3415668 0.77 EED (0.33) TDP1KMT2A
SCHEMBL18184989 0.76 TDP1 (0.44) TDP1ALDH1A1TSHRSMN1; SMN2L3MBTL1
SCHEMBL15329771 0.74 TDP1 (0.37) TDP1ALDH1A1HTTTSHRSMN1; SMN2
SCHEMBL18185023 0.72 TDP1 (0.41) TDP1ALDH1A1TSHRSMN1; SMN2GPR35
SCHEMBL159208 0.71 ALDH1A1 (0.42) TDP1ALDH1A1HTTTSHRSMN1; SMN2
SCHEMBL1922192 0.71 ALDH1A1 (0.31) TDP1ALDH1A1POLBHSD17B10CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2964642-B1 INHIBITORS OF BRUTON'S TYROSINE KINASE HOFFMANN LA ROCHE (CH) 2017-11-15 EP disclosed
US-9663494-B2 Inhibitors of bruton's tyrosine kinase HOFFMANN-LA ROCHE INC. (US) 2017-05-30 US disclosed
EP-2964642-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE F. Hoffmann-La Roche AG (CH) 2016-01-13 EP disclosed
US-20150376166-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE HOFFMANN-LA ROCHE INC. (US) 2015-12-31 US disclosed
WO-2014135474-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE F. HOFFMANN-LA ROCHE AG (CH) 2014-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150376166-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE BTK, SYK, LYN TDP1 232/4885ALDH1A1 3619/4885HTT 4509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.